Show simple item record

dc.contributor.authorIllidge, Timothy M
dc.contributor.authorMcKenzie, H
dc.contributor.authorMayes, S
dc.contributor.authorBates, A
dc.contributor.authorDavies, A
dc.contributor.authorPettengell, R
dc.contributor.authorStanton, L
dc.contributor.authorCozens, K
dc.contributor.authorHampson, Grace
dc.contributor.authorDive, Caroline
dc.contributor.authorZivanovic, M
dc.contributor.authorTipping, Jill
dc.contributor.authorGallop-Evans, E
dc.contributor.authorRadford, John A
dc.contributor.authorJohnson, P
dc.date.accessioned2016-02-18T15:06:55Zen
dc.date.available2016-02-18T15:06:55Zen
dc.date.issued2016-02-05en
dc.identifier.citationShort duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. 2016: Br J Haematolen
dc.identifier.issn1365-2141en
dc.identifier.pmid26849853en
dc.identifier.doi10.1111/bjh.13954en
dc.identifier.urihttp://hdl.handle.net/10541/596637en
dc.description.abstractWe report a phase II study to evaluate the efficacy and toxicity of abbreviated immunochemotherapy followed by (90) Y Ibritumomab tiuxetan ((90) Y-IT) in patients with recurrent follicular lymphoma. Of the 52 patients enrolled, 50 were treated with three cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone), followed by (90) Y-IT regimen (15 MBq/kg, maximum 1200 MBq) preceded by two infusions of 250 mg/m(2) rituximab. The overall response rate was 98% with complete response (CR) 30% and partial response (PR) 68%. 18 patients with a PR following chemotherapy improved to a CR following (90) Y-IT: a conversion rate of 40%. Seven patients with PR following (90) Y-IT subsequently improved to a CR 12-18 months later, leading to an overall CR rate of 44%. With a median follow-up of 5 years, median progression-free survival was 23·1 months and overall survival was 77·5% at 5 years. High trough serum rituximab levels (median 112 μg/ml; range 52-241) were attained after four doses of rituximab, prior to (90) Y-IT; this was not found to influence response rates. The treatment was well tolerated with few (13·5%) grade 3 or 4 infective episodes and manageable haematological toxicity. Abbreviated immunochemotherapy followed by (90) Y-IT is an effective and well-tolerated treatment in recurrent follicular lymphoma patients previously exposed to rituximab.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to British journal of haematologyen
dc.titleShort duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.en
dc.typeArticleen
dc.contributor.departmentManchester Academic Health Sciences Centre, University of Manchester, Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalBritish Journal of Haematologyen
dc.description.collectionLymphoma Research Teamen
html.description.abstractWe report a phase II study to evaluate the efficacy and toxicity of abbreviated immunochemotherapy followed by (90) Y Ibritumomab tiuxetan ((90) Y-IT) in patients with recurrent follicular lymphoma. Of the 52 patients enrolled, 50 were treated with three cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone), followed by (90) Y-IT regimen (15 MBq/kg, maximum 1200 MBq) preceded by two infusions of 250 mg/m(2) rituximab. The overall response rate was 98% with complete response (CR) 30% and partial response (PR) 68%. 18 patients with a PR following chemotherapy improved to a CR following (90) Y-IT: a conversion rate of 40%. Seven patients with PR following (90) Y-IT subsequently improved to a CR 12-18 months later, leading to an overall CR rate of 44%. With a median follow-up of 5 years, median progression-free survival was 23·1 months and overall survival was 77·5% at 5 years. High trough serum rituximab levels (median 112 μg/ml; range 52-241) were attained after four doses of rituximab, prior to (90) Y-IT; this was not found to influence response rates. The treatment was well tolerated with few (13·5%) grade 3 or 4 infective episodes and manageable haematological toxicity. Abbreviated immunochemotherapy followed by (90) Y-IT is an effective and well-tolerated treatment in recurrent follicular lymphoma patients previously exposed to rituximab.


This item appears in the following Collection(s)

Show simple item record